TIDMPRTC
PureTech Health PLC
16 July 2020
16 July 2020
PureTech Health plc
PureTech Founded Entity Vor Biopharma Appoints Daniella Beckman
to its Board of Directors
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering,
developing and commercialising highly differentiated medicines for
devastating diseases, is pleased to note that its Founded Entity,
Vor Biopharma, today announced it has appointed Daniella Beckman to
its Board of Directors. Ms Beckman is an experienced biotech
finance leader who currently serves as chief financial officer at
Tango Therapeutics. The appointment follows the hiring of
Christopher Slapak, MD, as chief medical officer and the recent
completion of a $110 million Series B financing round.
The full text of the announcement from Vor is as follows:
Vor Biopharma Appoints Daniella Beckman to its Board of
Directors
CAMBRIDGE, Mass., - July 16, 2020 - Vor Biopharma , an oncology
company pioneering engineered haematopoietic stem cells (eHSCs) for
the treatment of cancer, today announced the appointment of
Daniella Beckman to its Board of Directors. The appointment of Ms
Beckman, an experienced biotech finance leader who currently serves
as Chief Financial Officer at Tango Therapeutics, follows the
hiring of Christopher Slapak, MD, as Chief Medical Officer and the
completion of a $110 million Series B financing round.
"Daniella is a fantastic addition to our Board of Directors and
we are honored to have her join at this important time for our
company," said Robert Ang, MBBS, MBA, Vor's President and Chief
Executive Officer. "Her expertise in financial strategy and
operations will be of great value to us as we leverage our recent
Series B funding round to further advance our lead product
candidate VOR33 towards clinical trials and continue to build out
our portfolio."
Ms Beckman joins Vor with deep financial and operational
experience across the biotechnology industry, having worked with
both private and publicly traded companies throughout her career.
At Tango Therapeutics, Ms Beckman oversees finance, investor
relations, and business development. Prior to joining Tango, Ms
Beckman was a consultant to early-stage biotechnology companies,
leading financial activities and building companies' financial
infrastructures. She also served as Interim Chief Financial Officer
for Neon Therapeutics. Previously, Ms Beckman was Chief Financial
Officer of Idenix Pharmaceuticals, where she was responsible for
finance, investor relations, and IT until the company was acquired
by Merck in 2014. Earlier in her career, she held various finance
positions at Coley Pharmaceuticals, Biogen Idec, and
PricewaterhouseCoopers (PwC). Ms Beckman received her BA in
business administration and accounting from Boston University and
is a Certified Public Accountant in Massachusetts. In addition to
Vor, Ms Beckman also serves on the Board of Directors of Translate
Bio as Chair of the Audit and the Nomination and Governance
Committees.
"The Series B financing is testament to the potential for eHSCs
to improve the treatment paradigm for patients with blood cancers
such as acute myeloid leukaemia," Ms Beckman said. "I am looking
forward to working with and supporting Vor as the company continues
to innovate to address cancer patients in need."
About Vor Biopharma
Vor Biopharma aims to transform the lives of cancer patients by
pioneering engineered haematopoietic stem cell (eHSC) therapies. By
removing biologically redundant proteins from eHSCs, these cells
become inherently invulnerable to complementary targeted therapies
while tumour cells are left susceptible, thereby unleashing the
potential of targeted therapies to benefit cancer patients in
need.
Vor's platform could be used to potentially change the treatment
paradigm of both haematopoietic stem cell transplants and targeted
therapies, such as antibody drug conjugates, bispecific antibodies
and CAR-T cell treatments.
Vor is based in Cambridge, Mass. and has a broad intellectual
property base, including in-licenses from Columbia University,
where foundational work was conducted by inventor and Vor
Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.
About VOR33
Vor's lead product candidate, VOR33, consists of engineered
haematopoietic stem cells (eHSCs) that lack the protein CD33. Once
these cells are transplanted into a cancer patient, we believe that
CD33 will become a far more cancer-specific target, potentially
avoiding toxicity to the normal blood and bone marrow associated
with CD33-targeted therapies. Vor aims to improve the therapeutic
window and effectiveness of CD33-targeted therapies, thereby
potentially broadening the clinical benefit to patients suffering
from acute myeloid leukaemia.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 24 products and product candidates, including two
that have been cleared by the US Food and Drug Administration
(FDA). All of the underlying programmes and platforms that resulted
in this pipeline of product candidates were initially identified or
discovered and then advanced by the PureTech team through key
validation points based on the Company's unique insights into the
biology of the brain, immune and gut, or BIG, systems and the
interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUVSARRAUBAUR
(END) Dow Jones Newswires
July 16, 2020 08:04 ET (12:04 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024